However, recent research suggests that weight loss drugs, such as semaglutide, may offer a promising non-surgical treatment ...

Weight reduction has been shown to alleviate symptoms of osteoarthritis of the knee, including pain. The effect of ...

Osteoarthritis, the most common form of arthritis, is primarily caused by wear and tear on the protective layer of cartilage ...

By Gina Kolata The blockbuster drug semaglutide, sold as Ozempic for diabetes and as Wegovy for weight loss, now has a new ...

For individuals with obesity and knee osteoarthritis, once-weekly semaglutide yields greater reductions in body weight and ...

A newly published study in the New England Journal of Medicine highlighted this week that Novo Nordisk’s (NVO) GLP-1 agonist ...

Semaglutide shows promise in treating knee osteoarthritis by reducing pain and weight, offering a safe alternative to traditional pharmacological interventions.

In a phase 3 clinical trial, an international team of researchers found that a weekly dose of 2.4 milligrams of semaglutide significantly beat placebo treatments for relieving knee osteoarthritis pain ...

Subcutaneous semaglutide is currently marketed under the brand name Wegovy for chronic weight management and to reduce the risk of major adverse cardiovascular events in adults with established ...

Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a ...

The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss ...

Today, The New England Journal of Medicine published results from Novo Nordisk's STEP 9 phase 3 clinical trial that studied semaglutide 2.4 mg compared to placebo as an adjunct to lifestyle ...